


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Use as many sheets as necessary)

## **Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/678,836       |
| Filing Date            | October 3, 2003  |
| First Named Inventor   | Manoussos Perros |
| Art Unit               | To be assigned   |
| Examiner Name          | To be assigned   |
| Attorney Docket Number | PC10925B         |

## **U.S. PATENT DOCUMENTS**

| EXAMINER<br>INITIAL | Cite<br>No. <sup>1</sup> | DOCUMENT<br>NUMBER<br>Number-Kind Code <sup>2</sup> | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant Figures Appear |
|---------------------|--------------------------|---|--------------------------------|--|--|
| <i>SN</i>           | AA                       | US 5,968,947  | 10/19/1999                     | Zeneca Limited                                     |  |
| <i>SN</i>           | AB                       | US 6,586,430  | 07/01/2003                     | Pfizer, Inc.                                       |  |

## **FOREIGN PATENT DOCUMENTS**

| EXAMINER<br>INITIAL | Cite<br>No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> Number <sup>4</sup> Kind<br>Code <sup>5</sup> (if known) | Publication<br>Date<br>MM-DD-<br>YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|---------------------|--------------------------|---|---------------------------------------|--|---|----------------|
| <i>SN</i>           | AC                       | WO 91/11172   | 08/08/1991                            | The University of Kansas                           |   |                |
|                     | AD                       | WO 94/02518   | 02/03/1994                            | The University of Kansas                           |   |                |
|                     | AE                       | WO 98/55148   | 12/10/1998                            | Janssen Pharmaceutica<br>N.V.                      |   |                |
|                     | AF                       | EP 0630887  | 05/20/1994                            | Zeneca Limited                                     |   |                |
|                     | AG                       | WO 97/19060   | 05/29/1997                            | Zeneca Limited                                     |   |                |
|                     | AH                       | WO 97/24325   | 07/10/1997                            | Takeda Chemical<br>Industries Ltd.                 |   |                |
|                     | AI                       | WO 98/02151   | 01/22/1998                            | Leukosite, Inc.                                    |   |                |
|                     | AJ                       | WO 98/25617   | 06/18/1998                            | Merck & Co., Inc.                                  |   |                |
|                     | AK                       | WO 98/25604   | 06/18/1998                            | Merck & Co., Inc.                                  |   |                |
|                     | AL                       | WO 99/37617   | 06/18/1998                            | Merck & Co., Inc.                                  |   |                |
|                     | AM                       | EP 0903349  | 08/10/1998                            | F. Hoffmann-La Roche AG                            |   |                |
| <i>SN</i>           | AN                       | WO 99/04794   | 02/04/1999                            | Merck & Co., Inc.                                  |   |                |

EXAMINER:

*E. Huang*

DATE CONSIDERED:


*1/28/05*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Comple if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/678,836       |
| Filing Date            | October 3, 2003  |
| First Named Inventor   | Manoussos Perros |
| Art Unit               | To be assigned   |
| Examiner Name          | To be assigned   |
| Attorney Docket Number | PC10925B         |

|      |    |             |            |                          |  |
|------|----|-------------|------------|--------------------------|--|
| 2/18 | AO | WO 99/17773 | 04/15/1999 | Smithkline Beecham Corp. |  |
| 2/18 | AP | WO 99/37619 | 07/29/1999 | Leukosite, Inc.          |  |
| 2/18 | AQ | WO 00/38680 | 07/06/2000 | Pfizer Limited           |  |

## **NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-------------------|-----------------------|---|----------------|
| 2/18              | AR                    | BERGE, et. al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Science</i> , 1977, 1-19, Vol 66., No. 1.  |                |
|                   | AS                    | CASCIERI, et. al., "The Chemokine/Chemokine Receptor Family: Potential and Progress for Therapeutic Intervention," <i>Current Opinion Chem. Biol.</i> 2000, 420-427, Vol. 4, No. 4.   |                |
|                   | AT                    | COMBADIÈRE, et. al., "Cloning and Functional Expression of CC CKR5, a Human Monocyte CC Chemokine Receptor Selective for MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES," <i>Journal of Leukocyte Biology</i> , 1996, 147-152, Vol. 60.                            |                |
|                   | AU                    | CONNOR, et. al., "VPR Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes," <i>Virology</i> , 1995, 935-944, Vol. 206, No. 2.  |                |
|                   | AV                    | DIMITROV, et. al., "Microculture Assay for Isolation of Human Immunodeficiency Virus Type 1 and for Titration of Infected Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Microbiology</i> , 1990, 734-737, Vol 28, No. 4.                          |                |
| 2/18              | AW                    | HESELGESSER, J., et. al., "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor," <i>Journal of Biological Chemistry</i> , 1998, 15687-15692, Vol. 273, No. 25.  |                |

ALL NOT receive the following  
For Application  
AF-AQ

|                      |                          |
|----------------------|--------------------------|
| EXAMINER: 2/18 Huang | DATE CONSIDERED: 4/28/05 |
|----------------------|--------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.